BRPI0504945A - método para a produção de vìrus recombinante contendo sequências de nucleotìdeos codificantes do todo ou parte de proteìnas heterólogas, constructos de dna, vìrus recombinantes resultantes e composições vacinais contendo tais vìrus recombinantes para imunizar contra flavivirus e/ou outros patógenos - Google Patents

método para a produção de vìrus recombinante contendo sequências de nucleotìdeos codificantes do todo ou parte de proteìnas heterólogas, constructos de dna, vìrus recombinantes resultantes e composições vacinais contendo tais vìrus recombinantes para imunizar contra flavivirus e/ou outros patógenos

Info

Publication number
BRPI0504945A
BRPI0504945A BRPI0504945-8A BRPI0504945A BRPI0504945A BR PI0504945 A BRPI0504945 A BR PI0504945A BR PI0504945 A BRPI0504945 A BR PI0504945A BR PI0504945 A BRPI0504945 A BR PI0504945A
Authority
BR
Brazil
Prior art keywords
recombinant viruses
viruses
virus
sequences
nucleotide sequences
Prior art date
Application number
BRPI0504945-8A
Other languages
English (en)
Inventor
Myrna Cristina Bonaldo
Ricardo Galler
Original Assignee
Fundacao Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Oswaldo Cruz filed Critical Fundacao Oswaldo Cruz
Priority to BRPI0504945A priority Critical patent/BRPI0504945B8/pt
Priority to PCT/BR2006/000237 priority patent/WO2007051267A2/en
Priority to US12/084,387 priority patent/US8828687B2/en
Priority to EP06804595.4A priority patent/EP1989316B1/en
Publication of BRPI0504945A publication Critical patent/BRPI0504945A/pt
Priority to US14/304,387 priority patent/US9539317B2/en
Publication of BRPI0504945A8 publication Critical patent/BRPI0504945A8/pt
Priority to US15/378,294 priority patent/US10286059B2/en
Publication of BRPI0504945B1 publication Critical patent/BRPI0504945B1/pt
Publication of BRPI0504945B8 publication Critical patent/BRPI0504945B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

MéTODO PARA à PRODUçãO DE VìRUS RECOMBINANTE CONTENDO SEQüêNCIAS DE NUCLEOTìDEOS CODIFICANTES DO TODO OU PARTE DE PROTEìNAS HETERóLOGAS, CONSTRUCTOS DE DNA, VìRUS RECOMBINANTES RESULTANTES E COMPOSIçõES VACINAIS CONTENDO TAIS VìRUS RECOMBINANTES PARA IMUNIZAR CONTRA FLAVIVIRUS E/OU OUTROS PATóGENOS O objeto da presente invenção é a produção de vírus recombinante pela clonagem e expressão de seqüências de nucleotídeos codificantes do todo ou parte de proteínas heterólogas, através do seguinte método: a) Modificação de seqüências nucleotídicas heterólogas de forma que as mesmas, ao serem clonadas e expressas no vírus vetor, possuam, na sua porção 5', nucleotídeos presentes no extremo 5' do gene NS1 deste vírus vetor ou de outros vírus ou seqüências funcionalmente equivalentes, e na sua porção 3', a região genómica correspondente ao todo ou parte dos domínios de haste e ancora da proteína E deste vírus vetor ou de outros vírus ou seqüências funcionalmente equivalentes, e assim não comprometendo a estrutura e a replicação do dito vírus vetor; b) Inserção das seqüência heterólogas modificadas em (a) na região intergênica ao nível da proteína estrutural E e da não estrutural NS1 do vírus vetor; c) Obtenção de vírus recombinante não patogênico e detentor de propriedades imunológicas, contendo as seqüências estavelmente integradas no genoma viral conforme inserção na região descrita em (b) e, assim, expressando o antígeno heterólogo de modo que o mesmo induza uma resposta imune apropriada. Adicionalmente, também são previstas composições vacinais para imunizar contra Flavivirus e/ou outros patógenos, a qual consiste, essencialmente, do vírus obtido conforme o método supracitado.
BRPI0504945A 2005-10-31 2005-10-31 Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos. BRPI0504945B8 (pt)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BRPI0504945A BRPI0504945B8 (pt) 2005-10-31 2005-10-31 Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
PCT/BR2006/000237 WO2007051267A2 (en) 2005-10-31 2006-10-31 Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions
US12/084,387 US8828687B2 (en) 2005-10-31 2006-10-31 Method for the production of recombinant virus, DNA constructs, recombinant virus and vaccine compositions
EP06804595.4A EP1989316B1 (en) 2005-10-31 2006-10-31 Method for the production of recombinant flavivirus, DNA constructs, recombinant flavivirus and vaccine compositions
US14/304,387 US9539317B2 (en) 2005-10-31 2014-06-13 Method for the production of recombinant virus, DNA constructs, recombinant virus and vaccine compositions
US15/378,294 US10286059B2 (en) 2005-10-31 2016-12-14 Method for the production of recombinant virus, DNA constructs, recombinant virus and vaccine compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0504945A BRPI0504945B8 (pt) 2005-10-31 2005-10-31 Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.

Publications (4)

Publication Number Publication Date
BRPI0504945A true BRPI0504945A (pt) 2007-08-07
BRPI0504945A8 BRPI0504945A8 (pt) 2015-12-22
BRPI0504945B1 BRPI0504945B1 (pt) 2021-06-08
BRPI0504945B8 BRPI0504945B8 (pt) 2022-08-02

Family

ID=38006220

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0504945A BRPI0504945B8 (pt) 2005-10-31 2005-10-31 Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.

Country Status (4)

Country Link
US (3) US8828687B2 (pt)
EP (1) EP1989316B1 (pt)
BR (1) BRPI0504945B8 (pt)
WO (1) WO2007051267A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027290A1 (pt) * 2016-08-10 2018-02-15 Fundação Oswaldo Cruz Cassete de expressão heteróloga, constructo de dna e composição vacinal para imunizar contra flavivirus e/ou outros patógenos

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1551782A (zh) 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
KR101074175B1 (ko) 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
WO2004045529A2 (en) 2002-11-15 2004-06-03 Acambis, Inc. West nile virus vaccine
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
EP2117588A4 (en) * 2007-02-09 2011-05-04 Sanofi Pasteur Biologics Co VIRAL VECTORS AND METHODS OF USE
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
US20120128713A1 (en) * 2009-03-16 2012-05-24 Sanofi Pasteur Limited Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus
BRPI0914507A2 (pt) * 2009-12-23 2012-04-10 Fundacao Oswaldo Cruz vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela
KR20260047644A (ko) 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University "immunoregulatory molecules and uses therefor"
US12178869B2 (en) 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
WO2019172982A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
GB201814563D0 (en) * 2018-09-07 2018-10-24 Univ Leuven Kath Chimeric flavivirus lyssavirus vaccines
EP3969047A4 (en) * 2019-05-15 2022-11-09 Codagenix Inc. ATTACHED YELLOW FEVER VIRUS AND ITS USE TO TREAT CANCER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977587B1 (en) * 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
CA2311395C (en) * 1997-11-28 2006-11-28 Replikun Biotech Pty Ltd Flavivirus expression and delivery system
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
AU2003267851B2 (en) * 2002-10-09 2007-07-05 Young-Min Lee Novel full-length genomic RNA of Japanese encephalitis virus, infectious JEV CDNA therefrom, and use thereof
WO2005040390A1 (en) * 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. A recombinant vaccine using yellow fever virus as vector
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018027290A1 (pt) * 2016-08-10 2018-02-15 Fundação Oswaldo Cruz Cassete de expressão heteróloga, constructo de dna e composição vacinal para imunizar contra flavivirus e/ou outros patógenos
US11230574B2 (en) 2016-08-10 2022-01-25 Fundação Oswaldo Cruz Heterologous expression cassette, DNA construct and vaccine composition to immunize against flavivirus and/or other pathogens

Also Published As

Publication number Publication date
BRPI0504945B8 (pt) 2022-08-02
EP1989316B1 (en) 2015-04-01
US20100297167A1 (en) 2010-11-25
US20170360916A9 (en) 2017-12-21
US10286059B2 (en) 2019-05-14
US20170157237A1 (en) 2017-06-08
WO2007051267A3 (en) 2007-07-05
US9539317B2 (en) 2017-01-10
BRPI0504945B1 (pt) 2021-06-08
US20160367656A9 (en) 2016-12-22
WO2007051267A8 (en) 2007-08-30
EP1989316A4 (en) 2011-01-05
US20150024003A1 (en) 2015-01-22
EP1989316A2 (en) 2008-11-12
WO2007051267A2 (en) 2007-05-10
US8828687B2 (en) 2014-09-09
BRPI0504945A8 (pt) 2015-12-22

Similar Documents

Publication Publication Date Title
BRPI0504945A (pt) método para a produção de vìrus recombinante contendo sequências de nucleotìdeos codificantes do todo ou parte de proteìnas heterólogas, constructos de dna, vìrus recombinantes resultantes e composições vacinais contendo tais vìrus recombinantes para imunizar contra flavivirus e/ou outros patógenos
Gething et al. Cloning and DNA sequence of double-stranded copies of haemagglutinin genes from H2 and H3 strains elucidates antigenic shift and drift in human influenza virus
JP2022512625A (ja) 生物学的製剤の投与のためのアルファウイルスベースのレプリコン
BRPI9905902B8 (pt) "molécula polinucleotídica isolada, plasmídeo, e método para produzir um vírus prrs norte-americano"
NZ586238A (en) Methods and compositions for immunizing pigs against porcine circovirus
BR0016145A (pt) Clones infecciosos
JP2012515557A5 (pt)
GB2209764A (en) Recombinant vaccinia virus
Graff et al. Mutational events in consecutive passages of hepatitis A virus strain GBM during cell culture adaptation
Wiener et al. Comparison of the reovirus serotype 1, 2, and 3 S3 genome segments encoding the nonstructural protein σNS
EP3158059B1 (en) Method for rapid generation of an attenuated rna virus
CN103352029A (zh) 一种乙脑/森林脑炎嵌合病毒及其应用
WO2006136448A3 (en) Attenuated sars and use as a vaccine
JP6747983B2 (ja) 感染性ｒｎａウイルスを迅速に生成するための方法
MX2022016287A (es) Secuencias de acidos nucleicos y de aminoacidos de adenovirus de gorila, vectores que contienen las mismas y usos de las mismas.
BRPI0904020B8 (pt) composição vacinal contra o vírus da dengue, e, kit
Haas et al. Analysis of the H gene, the central untranslated region and the proximal coding part of the F gene of wild-type and vaccine canine distemper viruses
CN107201370A (zh) 一种dna分子与重组病毒及它们的制备方法和用途
Zheng et al. A simple method for developing an infectious cDNA clone of Japanese encephalitis virus
CN107635579A (zh) 非天然发生的猪生殖和呼吸综合征病毒(prrsv)和使用方法
Guo et al. Recombinant adenovirus expression of FMDV P1-2A and 3C protein and its immune response in mice
US8895028B2 (en) Methods and compositions for dengue virus 3 (DV3) infectious clone
US20220088169A1 (en) Virus vaccine
CA2453300A1 (en) Chimeric chains that code for proteins that induce effects directed against viruses
WO2002068662A8 (en) Plasmid originated from bifidobacterium, recombinant expression vector using the plasmid and transformation method

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 15/66 , C12N 15/86

Ipc: C12N 15/66 (2006.01), C12N 15/86 (2006.01), C12N 1

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICACAO DA PUBLICACAO DEVIDO A INCORRECOES NO TITULO DO RELATORIO DE EXAME TECNICO E NO QUADRO 1 DO PARECER DE DEFERIMENTO.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2005, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICACAO DO QUADRO 1 DO PARECER DE DEFERIMENTO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2631 DE 08/06/2021 QUANTO AO QUADRO REIVINDICATORIO E AOS DESENHOS.